Advertisement

Endocrine

, Volume 59, Issue 3, pp 585–592 | Cite as

Drug interactions in users of tablet vs. oral liquid levothyroxine formulations: a real-world evidence study in primary care

  • Valeria Guglielmi
  • Alfonso Bellia
  • Elisa Bianchini
  • Gerardo Medea
  • Iacopo Cricelli
  • Paolo Sbraccia
  • Davide Lauro
  • Claudio Cricelli
  • Francesco LapiEmail author
Original Article

Abstract

Purpose

Several medications may interact with levothyroxine (LT4) intestinal absorption or metabolism, thus reducing its bioavailability. We investigated the variability of thyroid stimulating hormone (TSH) levels and prescribed daily dosages (PDDs) of LT4 before and during potential drug–drug interactions (DDIs) in users of tablets vs. oral liquid LT4 formulations.

Methods

By using the Italian general practice Health Search Database (HSD), we retrospectively selected adult patients with at least one LT4 prescription from 2012 to 2015 and at least 1 year of clinical history recorded. The incident prescription of interacting medications (e.g., proton pump inhibitors, calcium or iron salts) was the index date. Analysis was carried out using a self-controlled study design.

Results

Overall, 3965 users of LT4 formed the study cohort (84.1% women, mean age 56 ± 16.5 years). TSH variability on the entry date was greater among liquid LT4 users than in those prescribed with tablets as shown by the difference between 75th and 25th centile, which were 3.01 and 3.8, respectively. The incidence rate ratio (IRR) for TSH variability did not differ between groups, before and during exposure to DDIs. In contrast, PDDs less likely increased during the exposure to DDI with oral liquid LT4 compared with tablets (IRR = 0.84; 95% CI: 0.77–0.92), especially in patients with post-surgical hypothyroidism (IRR = 0.75; 95% CI: 0.64–0.85).

Conclusions

In clinical practice, the use of oral liquid LT4 is not associated with increased PDDs, compared with tablets formulation, during exposure to DDIs. These results support the need for individualizing LT4 formulation to prescribe, especially in patients with various comorbidities and complex therapeutic regimens.

Keywords

Tablet levothyroxine Oral liquid levothyroxine Drug–drug interactions Gastrointestinal absorption Primary care Prescribed daily dosages 

Notes

Funding

This study was supported by IBSA. The funding institution had no role in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, the preparation, review, or approval of the manuscript, or the decision to submit the manuscript for publication.

Compliance with ethical standards

Conflict of interest

Dr. I. Cricelli and Dr. F. Lapi provided consultancies in protocol preparation for epidemiological studies and data analyses for Angelini, Alfa Wassermann, Bayer, and IBSA. Dr. C. Cricelli, and Dr. G. Medea provided clinical consultancies for Angelini, Alfa Wassermann, Bayer, and IBSA. Dr. V. Guglielmi, Dr. A. Bellia, Dr. E. Bianchini, Prof. P. Sbraccia, and Prof. D. Lauro, have no conflict of interest to disclose.

Ethical approval

This is an observational, retrospective, non-interventional study. According to a by-law on the classification and implementation of observational drug-related research, as issued by the Italian National Drug Agency (an entity belonging to the Italian Ministry of Health), the present study does not require approval by an Ethics Committee in Italy (Italian Drug Agency note of 3rd August 2007).

References

  1. 1.
    J.R. Garber, R.H. Cobin, H. Gharib, J.V. Hennessey, I. Klein, J.I. Mechanick, R. Pessah-Pollack, P.A. Singer, K.A. Woeber, Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22(12), 1200–1235 (2012).  https://doi.org/10.1089/thy.2012.0205 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    A.J. Chakera, S.H. Pearce, B. Vaidya, Treatment for primary hypothyroidism: current approaches and future possibilities. Drug. Des. Devel. Ther. 6, 1–11 (2012).  https://doi.org/10.2147/DDDT.S12894 CrossRefPubMedGoogle Scholar
  3. 3.
    W.E. Visser, E.C. Friesema, T.J. Visser, Minireview: thyroid hormone transporters: the knowns and the unknowns. Mol. Endocrinol. 25(1), 1–14 (2011).  https://doi.org/10.1210/me.2010-0095 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    M.T. Hays, Localization of human thyroxine absorption. Thyroid 1(3), 241–248 (1991).  https://doi.org/10.1089/thy.1991.1.241 CrossRefPubMedGoogle Scholar
  5. 5.
    M. Centanni, L. Gargano, G. Canettieri, N. Viceconti, A. Franchi, G. Delle Fave, B. Annibale, Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N. Engl. J. Med. 354(17), 1787–1795 (2006)CrossRefGoogle Scholar
  6. 6.
    C. Virili, G. Bassotti, M.G. Santaguida, R. Iuorio, S.C. Del Duca, V. Mercuri, A. Picarelli, P. Gargiulo, L. Gargano, M. Centanni, Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J. Clin. Endocrinol. Metab. 97(3), E419–E422 (2012).  https://doi.org/10.1210/jc.2011-1851 CrossRefPubMedGoogle Scholar
  7. 7.
    M. Ruchala, E. Szczepanek-Parulska, A. Zybek, The influence of lactose intolerance and other gastro-intestinal tract disorders on L-thyroxine absorption. Endokrynol. Pol. 63(4), 318–323 (2012)PubMedGoogle Scholar
  8. 8.
    R. Padwal, D. Brocks, A.M. Sharma, A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes. Rev. 11(1), 41–50 (2010).  https://doi.org/10.1111/j.1467-789X.2009.00614.x CrossRefPubMedGoogle Scholar
  9. 9.
    G. Ianiro, F. Mangiola, T.A. Di Rienzo, S. Bibbo, F. Franceschi, A.V. Greco, A. Gasbarrini, Levothyroxine absorption in health and disease, and new therapeutic perspectives. Eur. Rev. Med. Pharmacol. Sci. 18(4), 451–456(2014)PubMedGoogle Scholar
  10. 10.
    L. Liwanpo, J.M. Hershman, Conditions and drugs interfering with thyroxine absorption. Best Pract. Res. Clin. Endocrinol. Metab. 23(6), 781–792 (2009).  https://doi.org/10.1016/j.beem.2009.06.006 CrossRefPubMedGoogle Scholar
  11. 11.
    M. Lombardo, A. Bellia, F. Mattiuzzo, A. Franchi, C. Ferri, E. Padua, V. Guglielmi, M. D’Adamo, G. Annino, P. Gentileschi, F. Iellamo, D. Lauro, M. Federici, P. Sbraccia, Frequent follow-up visits reduce weight regain in long-term management after bariatric surgery. Bariatr. Surg. Pract. Patient Care 10(3), 119–125(2015).CrossRefGoogle Scholar
  12. 12.
    S. Benvenga, L. Bartolone, S. Squadrito, F. Lo Giudice, F. Trimarchi, Delayed intestinal absorption of levothyroxine. Thyroid 5(4), 249–253 (1995).  https://doi.org/10.1089/thy.1995.5.249 CrossRefPubMedGoogle Scholar
  13. 13.
    T.G. Bach-Huynh, B. Nayak, J. Loh, S.Soldin, J. Jonklaas, Timing of levothyroxine administration affects serum thyrotropin concentration. J. Clin. Endocrinol. Metab. 94(10), 3905–3912 (2009).  https://doi.org/10.1210/jc.2009-0860 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    N. Bolk, T.J. Visser, J. Nijman, I.J. Jongste, J.G. Tijssen, A. Berghout, Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Arch. Intern. Med. 170(22), 1996–2003 (2010).  https://doi.org/10.1001/archinternmed.2010.436 CrossRefPubMedGoogle Scholar
  15. 15.
    R.D. Utiger, Estrogen, thyroxine binding in serum, and thyroxine therapy. N. Engl. J. Med. 344(23), 1784–1785 (2001).  https://doi.org/10.1056/NEJM200106073442310 CrossRefPubMedGoogle Scholar
  16. 16.
    S.A. Hamed, The effect of antiepileptic drugs on thyroid hormonal function: causes and implications. Expert. Rev. Clin. Pharmacol. 8(6), 741–750 (2015).  https://doi.org/10.1586/17512433.2015.1091302 CrossRefPubMedGoogle Scholar
  17. 17.
    C.S. Yue, C. Scarsi, M.P. Ducharme, Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung. 62(12), 631–636 (2012).  https://doi.org/10.1055/s-0032-1329951 CrossRefPubMedGoogle Scholar
  18. 18.
    R. Vita, P. Fallahi, A. Antonelli, S. Benvenga, The administration of L-thyroxine as soft gel capsule or liquid solution. Expert. Opin. Drug. Deliv. 11(7), 1103–1111 (2014).  https://doi.org/10.1517/17425247.2014.918101 CrossRefPubMedGoogle Scholar
  19. 19.
    D. Pabla, F. Akhlaghi, H. Zia, A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur. J. Pharm. Biopharm. 72(1), 105–110 (2009).  https://doi.org/10.1016/j.ejpb.2008.10.008S0939-6411(08)00387-1 CrossRefPubMedGoogle Scholar
  20. 20.
    A. Cassio, S. Monti, A. Rizzello, I. Bettocchi, F. Baronio, G. D’Addabbo, M.O. Bal, A. Balsamo, Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism. J. Pediatr. 162(6), 1264–1269 (2013).  https://doi.org/10.1016/j.jpeds.2012.11.070 CrossRefPubMedGoogle Scholar
  21. 21.
    R. Vita, F. Di Bari, S. Benvenga, Oral liquid levothyroxine solves the problem of tablet levothyroxine malabsorption due to concomitant intake of multiple drugs. Expert. Opin. Drug. Deliv. 14(4), 467–472 (2017).  https://doi.org/10.1080/17425247.2017.1290604 CrossRefPubMedGoogle Scholar
  22. 22.
    R. Vita, G. Saraceno, F. Trimarchi, S. Benvenga, Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by proton-pump inhibitors. J. Clin. Endocrinol. Metab. 99(12), 4481–4486 (2014).  https://doi.org/10.1210/jc.2014-2684 CrossRefPubMedGoogle Scholar
  23. 23.
    C. Virili, P. Trimboli, F. Romanelli, M. Centanni, Liquid and softgel levothyroxine use in clinical practice: state of the art. Endocrine 54(1), 3–14 (2016).  https://doi.org/10.1007/s12020-016-1035-1. CrossRefPubMedGoogle Scholar
  24. 24.
    P. Fallahi, S.M. Ferrari, A. Antonelli, In patients with subclinical hypothyroidism while in therapy with tablet L-T4, the liquid L-T4 formulation is more effective in restoring euthyroidism. Endocr. Pract. 23(2), 170–174 (2017).  https://doi.org/10.4158/EP161545.OR CrossRefPubMedGoogle Scholar
  25. 25.
    C.P. Lombardi, R. Bocale, A. Barini, A. D’Amore, M. Boscherini, R. Bellantone, Comparative study between the effects of replacement therapy with liquid and tablet formulations of levothyroxine on mood states, self-perceived psychological well-being and thyroid hormone profile in recently thyroidectomized patients. Endocrine 55(1), 51–59 (2017).  https://doi.org/10.1007/s12020-016-1003-9. CrossRefPubMedGoogle Scholar
  26. 26.
    R. Ferrara, V. lentile, V. Arcoraci, C. Ferrajolo, C. Piccinni, A. Fontana, S. Benvenga, G. Trifiro, Treatment pattern and frequency of serum TSH measurement in users of different levothyroxineformulations: a population-based study during the years 2009–2015. Endocrine (2017).10.1007/s12020-017-1242-4CrossRefPubMedGoogle Scholar
  27. 27.
    G.M. Leggio, T. Incognito, G. Privitera, M.R. Marano, F. Drago, Comparative bioavailability of different formulations of levothyroxine and liothyronine in healthy volunteers. J. Endocrinol. Invest. 29(11), RC35–RC38 (2006). 10.1007/BF03349205CrossRefPubMedGoogle Scholar
  28. 28.
    P. Fallahi, S.M. Ferrari, I. Ruffilli, A. Antonelli, Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: a case series. BMC. Gastroenterol. 16, 22 (2016).  https://doi.org/10.1186/s12876-016-0439-y CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    M.G. Santaguida, C. Virili, S.C. Del Duca, M. Cellini, I. Gatto, N. Brusca, C. De Vito, L. Gargano, M. Centanni, Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. Endocrine 49(1), 51–57 (2015).  https://doi.org/10.1007/s12020-014-0476-7 CrossRefPubMedGoogle Scholar
  30. 30.
    D. Ribichini, G. Fiorini, A. Repaci, V. Castelli, L. Gatta, E. Vaira, R. Pasquali, Tablet and oral liquid Lthyroxineformulation in the treatment of naive hypothyroid patients with Helicobacter pyloriinfection. Endocrine (2016). 10.1007/s12020-016-1167-3CrossRefPubMedGoogle Scholar
  31. 31.
    I. Pirola, A.M. Formenti, E. Gandossi, F. Mittempergher, C. Casella, B. Agosti, C. Cappelli, Oral liquid L-thyroxine (L-t4) may be better absorbed compared to L-T4 tablets following bariatric surgery. Obes. Surg. 23(9), 1493–1496 (2013).  https://doi.org/10.1007/s11695-013-1015-y CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    P. Fallahi, S.M. Ferrari, S. Camastra, U. Politti, I. Ruffilli, R. Vita, G. Navarra, S. Benvenga, A. Antonelli, TSH normalization in bariatric surgery patients after the switch from L-thyroxine in tablet to an oral liquid formulation. Obes. Surg. 27(1), 78–82 (2017).  https://doi.org/10.1007/s11695-016-2247-4 CrossRefPubMedGoogle Scholar
  33. 33.
    S.A. Irving, T. Vadiveloo, G.P. Leese, Drugs that interact with levothyroxine: an observational study from the thyroid epidemiology, audit and research study (TEARS). Clin. Endocrinol.82(1), 136–141 (2015).  https://doi.org/10.1111/cen.12559 CrossRefGoogle Scholar
  34. 34.
    I. Sachmechi, D.M. Reich, M. Aninyei, F. Wibowo, G. Gupta, P.J. Kim, Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr. Pract. 13(4), 345–349 (2007). 10.4158/EP.13.4.345CrossRefPubMedGoogle Scholar
  35. 35.
    C.J. Diskin, T.J. Stokes, L.M. Dansby, L. Radcliff, T.B. Carter, Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement. Int. Urol. Nephrol. 39(2), 599–602 (2007).  https://doi.org/10.1007/s11255-006-9166-6 CrossRefPubMedGoogle Scholar
  36. 36.
    J.W. Dietrich, K. Gieselbrecht, R.W. Holl, B.O. Boehm, Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Horm. Metab. Res. 38(1), 57–59 (2006).  https://doi.org/10.1055/s-2006-924980 CrossRefPubMedGoogle Scholar
  37. 37.
    S. Ananthakrishnan, L.E. Braverman, R.M. Levin, B. Magnani, E.N. Pearce, The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid 18(5), 493–498 (2008).  https://doi.org/10.1089/thy.2007.0381 CrossRefPubMedGoogle Scholar
  38. 38.
    V. Guglielmi, A. Bellia, S. Pecchioli, G. Medea, D. Parretti, D. Lauro, P. Sbraccia, M. Federici, I. Cricelli, C. Cricelli, F. Lapi, What is the actual epidemiology of familial hypercholesterolemia in Italy? Evidence from a national primary care database. Int. J. Cardiol. 223, 701–705 (2016).  https://doi.org/10.1016/j.ijcard.2016.08.269 CrossRefPubMedGoogle Scholar
  39. 39.
    V. Guglielmi, A. Bellia, S. Pecchioli, D. Della-Morte, D. Parretti, I. Cricelli, G. Medea, P. Sbraccia, D. Lauro, C. Cricelli, F. Lapi, Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care. Atherosclerosis 263, 36–41 (2017).  https://doi.org/10.1016/j.atherosclerosis.2017.05.018 CrossRefGoogle Scholar
  40. 40.
    C. Cricelli, G. Mazzaglia, F. Samani, M. Marchi, A. Sabatini, R. Nardi, G. Ventriglia, A.P. Caputi, Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J. Public Health Med. 25(3), 254–257 (2003)CrossRefGoogle Scholar
  41. 41.
    G. Trifiro, P. Morabito, L. Cavagna, C. Ferrajolo, S. Pecchioli, M. Simonetti, E. Bianchini, G. Medea, C. Cricelli, A.P. Caputi, G. Mazzaglia, Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Annrheumdis 72(5), 694–700 (2013).  https://doi.org/10.1136/annrheumdis-2011-201254 CrossRefGoogle Scholar
  42. 42.
    F. Lapi, M. Simonetti, R. Michieli, A. Pasqua, M.L. Brandi, B. Frediani, C. Cricelli, G. Mazzaglia, Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. Bone 50(1), 85–90 (2012).  https://doi.org/10.1016/j.bone.2011.09.048 CrossRefPubMedGoogle Scholar
  43. 43.
    G. Giussani, C. Cricelli, F. Mazzoleni, I. Cricelli, A. Pasqua, S. Pecchioli, F. Lapi, E. Beghi, Prevalence and incidence of epilepsy in Italy based on a nationwide database. Neuroepidemiology 43(3-4), 228–232 (2014).  https://doi.org/10.1159/000368801 CrossRefPubMedGoogle Scholar
  44. 44.
    P. Sathi, S. Kalyan, C.L. Hitchcock, M. Pudek, J.C. Prior, Progesterone therapy increases free thyroxine levels--data from a randomized placebo-controlled 12-week hot flush trial. Clin. Endocrinol. 79(2), 282–287 (2013).  https://doi.org/10.1111/cen.12128 CrossRefGoogle Scholar
  45. 45.
    G. Trifiro, F. Parrino, J. Sultana, F. Giorgianni, C. Ferrajolo, E. Bianchini, G. Medea, S. Benvenga, I. Cricelli, C. Cricelli, F. Lapi, Drug interactions with levothyroxine therapy in patients with hypothyroidism: observational study in general practice. Clin. Drug. Investig. 35(3), 187–195 (2015).  https://doi.org/10.1007/s40261-015-0271-0 CrossRefPubMedGoogle Scholar
  46. 46.
    B.R. Haugen, Drugs that suppress TSH or cause central hypothyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 23(6), 793–800 (2009).  https://doi.org/10.1016/j.beem.2009.08.003 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    M. Salas, A. Hofman, B.H. Stricker, Confounding by indication: an example of variation in the use of epidemiologic terminology. Am. J. Epidemiol. 149(11), 981–983 (1999)CrossRefGoogle Scholar
  48. 48.
    L. Romanelli, E. Mhillaj, V. Cuomo, The importance of reporting unexpected drug failure. J. Pharmacovigil. 4(1), 1–2 (2016).  https://doi.org/10.4172/2329-6887.1000e148 CrossRefGoogle Scholar
  49. 49.
    D. Pincus, T. Gomes, C. Hellings, H. Zheng, J.M. Paterson, M.M. Mamdani, D.N. Juurlink, A population-based assessment of the drug interaction between levothyroxine and warfarin. Clin. Pharmacol. Ther. 92(6), 766–770 (2012).  https://doi.org/10.1038/clpt.2012.171 CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    P.N. Taylor, A. Iqbal, C. Minassian, A. Sayers, M.S. Draman, R. Greenwood, W. Hamilton, O. Okosieme, V. Panicker, S.L. Thomas, C. Dayan, Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern Med 174(1), 32–39 (2014).  https://doi.org/10.1001/jamainternmed.2013.11312 CrossRefPubMedGoogle Scholar
  51. 51.
    Y. Ingrasciotta, J. Sultana, F. Giorgianni, A.P. Caputi, V. Arcoraci, D.U. Tari, C. Linguiti, M. Perrotta, A. Nucita, F. Pellegrini, A. Fontana, L. Cavagna, D. Santoro, G. Trifiro, The burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern Italy. PLoS. ONE. 9(2), e8907 (2014).  https://doi.org/10.1371/journal.pone.0089072 CrossRefGoogle Scholar
  52. 52.
    W. Willett, An overview of issues related to the correction of non-differential exposure measurement error in epidemiologic studies. Stat. Med. 8(9), 1031–1040 (1989). discussion 1033–1071CrossRefGoogle Scholar
  53. 53.
    I. Donangelo, G.D. Braunstein, Update on subclinical hyperthyroidism. Am. Fam. Physician. 83(8), 933–938 (2011)PubMedGoogle Scholar
  54. 54.
    A.M. Formenti, G. Mazziotti, R. Giubbini, A. Giustina, Treatment of hypothyroidism: all that glitters is gold? Endocrine 52(3), 411–413 (2016).  https://doi.org/10.1007/s12020-016-0882-0 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Valeria Guglielmi
    • 1
  • Alfonso Bellia
    • 1
  • Elisa Bianchini
    • 2
  • Gerardo Medea
    • 3
  • Iacopo Cricelli
    • 2
  • Paolo Sbraccia
    • 1
  • Davide Lauro
    • 1
  • Claudio Cricelli
    • 3
  • Francesco Lapi
    • 2
    Email author
  1. 1.Department of Systems MedicineUniversity of Rome “Tor Vergata”RomeItaly
  2. 2.Health SearchItalian College of General Practitioners and Primary CareFlorenceItaly
  3. 3.Italian College of General Practitioners and Primary CareFlorenceItaly

Personalised recommendations